United-Guardian Reports 2025 Financial Results

United-Guardian (NASDAQ:UG) reported FY2025 net sales of $10,545,468, down 13% from 2024, and net income of $2,105,738 ($0.46 per share) versus $3,250,875 ($0.71) in 2024.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

United-Guardian (NASDAQ:UG) reported FY2025 net sales of $10,545,468, down 13% from 2024, and net income of $2,105,738 ($0.46 per share) versus $3,250,875 ($0.71) in 2024. Sales of pharmaceuticals and medical lubricants rose, while cosmetic ingredient sales declined.

The company cited distributor inventory overstock, weaker China demand, and tariffs; it plans marketing and distribution initiatives, including additional Renacidin formulary placements.

Positive

Pharmaceutical sales +15% in 2025
Medical lubricant sales +4% in 2025
Net income of $2.11M maintained despite sales decline
Renacidin added to two major pharmacy benefit formularies

Negative

Net sales down 13% to $10.55M in 2025
Net income declined 35% year-over-year
Income from operations fell to $2.24M from $3.65M
Stockholders' equity decreased to $11.23M

Argus Mar 27 session

+4.96% close to close Open Argus

Details

News Market Reaction – UG

On Mar 27, the day this news came out, UG closed 4.96% above the previous close.

Data tracked by StockTitan Argus for the Mar 27 session.

Key Figures

Net sales 2025: $10,545,468 Net sales 2024: $12,181,971 Net income 2025: $2,105,738 +5 more

Net sales 2025: $10,545,468; FY 2025 net sales
Net sales 2024: $12,181,971; FY 2024 net sales
Net income 2025: $2,105,738; FY 2025 net income
Net income 2024: $3,250,875; FY 2024 net income
EPS 2025: $0.46; FY 2025 earnings per share
EPS 2024: $0.71; FY 2024 earnings per share
Pharma sales growth: 15%; Increase in pharmaceutical sales in 2025 vs 2024
Medical lubricants growth: 4%; Increase in medical lubricants sales in 2025 vs 2024

Previous Earnings Reports

5 past events · Latest: Nov 06

Same Type 5 events

Nov 06
Q3 2025 earnings

24h Move

-6.3%

Q3 and nine‑month 2025 sales and income declined versus prior year.
Aug 08
Q2 2025 earnings

24h Move

-0.5%

Q2 and H1 2025 revenue and net income fell year over year.
May 08
Q1 2025 earnings

24h Move

+0.6%

Sharp declines in sales and income driven by cosmetic ingredient weakness.
Mar 21
FY 2024 earnings

24h Move

-3.0%

FY 2024 delivered higher sales and net income with strong segment growth.
Nov 08
Q3 2024 earnings

24h Move

-12.1%

Q3 2024 and nine‑month results showed rising sales and earnings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

medicare rebates, drug formularies, pharmacy benefit managers

3 terms

medicare rebates regulatory

"combined with a decrease in Medicare rebates."

Payments or refunds required by a government-run health insurance program that reduce the net price paid for medical services, drugs, or supplies. Think of it as a store issuing a post-sale discount or refund because of a rule or contract; for investors, these rebates shrink reported sales and margins, affect cash flow timing, and introduce regulatory and policy risk that can change a healthcare company's revenue outlook.

drug formularies regulatory

"seeking its inclusion on additional drug formularies."

A drug formulary is a curated list of prescription medicines that an insurer, hospital, or pharmacy program approves for coverage and preferred use. It matters to investors because placement on, or exclusion from, a formulary determines how easily patients can get a drug and at what out‑of‑pocket price, directly affecting sales and revenue; think of it like which products a grocery chain chooses to stock and promote on its shelves.

pharmacy benefit managers regulatory

"we recently received approval from two major pharmacy benefit managers."

Pharmacy benefit managers are companies that manage prescription drug plans for health insurers, employers, and other organizations. They negotiate prices with drug manufacturers, decide which medications are covered, and handle the distribution of prescriptions. Their role can impact healthcare costs and drug availability, making them an important factor for investors to consider in the healthcare and pharmaceutical industries.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

03/27/2026 - 09:00 AM EDT

HAUPPAUGE, N.Y., March 27, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) reported that net sales and net income for FY 2025 decreased compared to FY 2024. Net sales for the year decreased by 13% from $12,181,971 in 2024 to $10,545,468 in 2025, generating net income of $3,250,875 ($0.71 per share) in 2024 compared to $2,105,738 ($0.46 per share) in 2025.

Donna Vigilante, President of United-Guardian, stated, “Our financial performance in 2025 was primarily impacted by the decrease in sales of our cosmetic ingredients. One of the issues we faced was excess inventory held by our largest cosmetic ingredient distributor, Ashland Specialty Ingredients (“ASI”). The inventory overstock led to reduced order quantities from ASI throughout the year. The situation was further impacted by decreased global demand for our products, particularly in China, where heightened competition from local Asian producers, and the impact of global tariffs, negatively impacted sales. In response to these challenges, we have been collaborating closely with our distributor in China to regain lost market share, offering competitive pricing where feasible, differentiating our products from the competition, and exploring new markets where cost pressures are less pronounced.”

“On a positive note, sales of pharmaceuticals and medical lubricants increased in 2025 compared to 2024, by 15% and by 4%, respectively. The increase in medical lubricants was driven by greater demand from two of our large contract manufacturer customers in China. The increase in pharmaceutical sales resulted from an increase in sales to all three of our national drug wholesalers, combined with a decrease in Medicare rebates. In 2025 we initiated a new marketing strategy to expand the domestic sales of Renacidin^® by increasing awareness of Renacidin and seeking its inclusion on additional drug formularies. I am happy to report that we recently received approval from two major pharmacy benefit managers. We believe that having Renacidin available on additional drug formularies will enhance patient access and will support the product’s long-term commercial growth. We are optimistic that this initiative, along with the new marketing and distribution agreements we entered into in 2025 for our cosmetic ingredients, will result in increased sales in the coming years.”

United-Guardian is a manufacturer of cosmetic ingredients, sexual wellness ingredients, pharmaceuticals, and medical lubricants.

Contact:	Donna Vigilante
	(631) 273-0900
	dvigilante@u-g.com

NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.

FINANCIAL RESULTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2025 AND 2024 STATEMENTS OF INCOME
	Years ended December 31,
	2025		2024

Net sales	$	10,545,468	$	12,181,971

Costs and expenses:
Cost of sales		5,404,328		5,721,584
Operating expenses		2,434,148		2,356,819
Research and development		463,644		456,779
Total costs and expenses		8,302,120		8,535,182
Income from operations		2,243,348		3,646,789
Other income:
Investment income		365,308		434,679
Net gain on marketable securities		34,359		26,989
Total other income		399,667		461,668

Income before provision for income taxes		2,643,015		4,108,457

Provision for income taxes		537,277		857,582
Net income	$	2,105,738	$	3,250,875

Earnings per common share (basic and diluted)	$	0.46	$	0.71

Weighted average shares (basic and diluted)		4,594,319		4,594,319

BALANCE SHEET DATA (condensed)
		December 31,
		2025		2024

Current assets:	$	12,201,397	$	12,665,551
Deferred tax asset, net		---		175,397
Property, plant, and equipment, net		907,182		956,387
Total assets		13,108,579		13,797,335

Current liabilities:		1,669,321		1,914,469
Deferred tax liability, net		207,246		---
Total liabilities		1,876,567		1,914,469

Stockholders’ equity		11,232,012		11,882,866
Total liabilities and stockholders’ equity	$	13,108,579	$	13,797,335

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did United-Guardian (UG) report a 13% sales decline in FY2025?

The company attributes the 13% FY2025 sales decline to lower cosmetic ingredient orders and weaker demand in China. According to the company, excess inventory at distributor ASI and heightened local competition and tariffs reduced orders and global demand.

How did United-Guardian (UG) achieve higher pharmaceutical sales in 2025?

Pharmaceutical sales rose 15% in 2025 driven by increased sales to national drug wholesalers and lower Medicare rebates. According to the company, broader distributor activity and formulary access supported the pharmaceutical revenue increase.

What is the FY2025 EPS and net income reported by United-Guardian (UG)?

United-Guardian reported FY2025 net income of $2,105,738 and EPS of $0.46. According to the company, this compares with $3,250,875 and $0.71 per share in FY2024, reflecting lower net sales and operating income.

What actions is United-Guardian (UG) taking to recover cosmetic ingredient sales?

The company is pursuing new marketing, distribution agreements, and competitive pricing to regain market share. According to the company, it is collaborating with its China distributor and exploring markets with less cost pressure to boost future sales.

Did United-Guardian (UG) report any balance sheet or liquidity changes for 2025?

Total assets fell modestly to $13.11M and stockholders' equity declined to $11.23M at year-end 2025. According to the company, current assets remained roughly stable while total liabilities decreased slightly year-over-year.

How might Renacidin formulary approvals affect United-Guardian (UG) going forward?

Formulary additions may improve patient access and support long-term commercial growth for Renacidin. According to the company, approval from two major pharmacy benefit managers should help expand domestic sales and distribution.

United-Guardian Reports 2025 Financial Results